JP2002524415A - 炎症を治療するための医薬組成物及び方法 - Google Patents

炎症を治療するための医薬組成物及び方法

Info

Publication number
JP2002524415A
JP2002524415A JP2000568493A JP2000568493A JP2002524415A JP 2002524415 A JP2002524415 A JP 2002524415A JP 2000568493 A JP2000568493 A JP 2000568493A JP 2000568493 A JP2000568493 A JP 2000568493A JP 2002524415 A JP2002524415 A JP 2002524415A
Authority
JP
Japan
Prior art keywords
nsaid
cox
nsaids
flurbiprofen
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000568493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002524415A5 (enExample
Inventor
ウィリアム ジェイ ウェクター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002524415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Loma Linda University filed Critical Loma Linda University
Publication of JP2002524415A publication Critical patent/JP2002524415A/ja
Publication of JP2002524415A5 publication Critical patent/JP2002524415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
JP2000568493A 1998-09-03 1999-09-03 炎症を治療するための医薬組成物及び方法 Pending JP2002524415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03
US09/146,395 1998-09-03
PCT/US1999/020261 WO2000013684A2 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and method for treatment of inflammation

Publications (2)

Publication Number Publication Date
JP2002524415A true JP2002524415A (ja) 2002-08-06
JP2002524415A5 JP2002524415A5 (enExample) 2006-10-19

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000568493A Pending JP2002524415A (ja) 1998-09-03 1999-09-03 炎症を治療するための医薬組成物及び方法

Country Status (13)

Country Link
US (1) US6472433B2 (enExample)
EP (1) EP1143958B8 (enExample)
JP (1) JP2002524415A (enExample)
CN (1) CN1391470A (enExample)
AT (1) ATE353010T1 (enExample)
AU (1) AU6026099A (enExample)
CA (1) CA2342628C (enExample)
CY (1) CY1106541T1 (enExample)
DE (1) DE69933049T2 (enExample)
DK (1) DK1143958T3 (enExample)
ES (1) ES2281981T3 (enExample)
PT (1) PT1143958E (enExample)
WO (1) WO2000013684A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
HRP20010309B1 (en) 1998-12-23 2005-06-30 Idea Ag Improved formulation for topical non-invasive application in vivo
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
CO5261556A1 (es) 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
KR20070086045A (ko) * 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2014015341A2 (en) * 2012-07-20 2014-01-23 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (zh) * 2021-09-23 2023-04-07 南京医科大学 R-酮咯酸在防治主动脉夹层和主动脉瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (it) 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5002007813; Ｅｘｐｅｒｉｅｎｔｉａ Ｖｏｌ．４７，Ｎｏ．３, 1991, ｐ２５７-２６１ *
JPN6009067488; Ａｇｅｎｔｓ　ａｎｄ　Ａｃｔｉｏｎｓ．　Ｓｕｐｐｌｅｍｅｎｔｓ Ｖｏｌ．４４, 1993, ｐ３１-３６ *
JPN6009067491; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．３６，Ｎｏ．６, 1996, ｐ５１３-５２０ *

Also Published As

Publication number Publication date
CN1391470A (zh) 2003-01-15
WO2000013684A3 (en) 2002-05-30
EP1143958A3 (en) 2002-08-21
EP1143958B1 (en) 2007-01-31
CA2342628C (en) 2009-07-07
US20010012849A1 (en) 2001-08-09
CY1106541T1 (el) 2012-01-25
DE69933049D1 (de) 2006-10-12
CA2342628A1 (en) 2000-03-16
DE69933049T2 (de) 2007-10-04
EP1143958B8 (en) 2007-05-23
DK1143958T3 (da) 2007-04-10
US6472433B2 (en) 2002-10-29
EP1143958A2 (en) 2001-10-17
ATE353010T1 (de) 2007-02-15
WO2000013684A2 (en) 2000-03-16
AU6026099A (en) 2000-03-27
PT1143958E (pt) 2007-04-30
ES2281981T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
JP2002524415A (ja) 炎症を治療するための医薬組成物及び方法
AU713569B2 (en) Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
US5382591A (en) Antipyretic and analgesic methods using optically pure R-ketorolac
CA2237306C (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
US5331000A (en) Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
ES2253810T3 (es) Uso de r-aines para la prevencion de la enfermedad de alzheimer.
JP2007533733A (ja) 食物摂取管理の方法
CA2362888C (en) Use of r-aryl propionic acids for producing medicaments to treat diseases in humans and animals, whereby said diseases can be therapeutically influenced by inhibiting the activation of nf-kb
WO2010120253A1 (en) Thiocolchicoside and non-steroidal anti-inflammatory drug combinations
JP2002534361A (ja) Ｃｏｘ−２選択的阻害剤ではないｃｏｘ阻害化合物から、ｃｏｘ−２選択的阻害剤への変換
MX2007001929A (es) Metodos y composiciones para suministro oral de acido farnesiltiosalicilico (fts).
AU2004222809B2 (en) Pharmaceutical Composition and Method for Treatment of Inflammation
TNSN00015A1 (fr) Nouveaux sels de morpholinobenzamide
JP2004535457A (ja) ピリダジノン誘導体の新しい用途
JP2002514208A (ja) 痴呆の治療及び予防におけるシクロオキシゲナーゼ−２阻害剤の使用方法
AU4602501A (en) Antipyretic and analgesic methods and compositions containing optically pure R-ketorolac

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111207

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120210